Learning Objectives:

1.  Categorize FDA approved ADCs in terms of their molecular characteristics
2. List and understand the landmark clinical trials leading to FDA approval of ADCs in breast cancer
3. Understand the drawbacks of IHC in determining ADC eligibility

Session date: 
05/09/2024 - 8:00am to 9:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dan Peiffer MD, PhD